{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"379.0","upperLimit":"518.0","value":"459.0"},{"groupId":"OG001","lowerLimit":"813.0","upperLimit":"1320.0","value":"1110.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"211"}],"units":"Participants"}],"title":"Duration of response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"486.0","upperLimit":"738.0","value":"563.0"},{"groupId":"OG001","lowerLimit":"933.0","upperLimit":"1602.0","value":"1282.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Duration for Complete responders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"description":"The duration of treatment response was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR, CRu, or PR as determined by the Independent Review Committee. The duration of response for complete responders was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR or CRu verified by bone marrow and lactate dehydrogenase (LDH).","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, Vincristine 1.4 mg/m\\^2 and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles Vincristine: Vincristine intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles.","id":"OG000","title":"R-CHOP"},{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, VELCADE 1.3 mg/m\\^2, and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day of a 21 day (3 week) cycle for 6 cycles VELCADE: VELCADE intravenous on Days 1,4,8, and 11 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles.","id":"OG001","title":"VcR-CAP"}],"paramType":"MEDIAN","populationDescription":"The response-evaluable population was defined as all participants who received at least 1 dose of study drug, had \\>= 1 measurable tumor mass (\\>1.5 cm in the longest dimension and \\>1.0 cm in the short axis) at baseline and had at least 1 post-baseline tumor assessment by Independent Review Committee, before any subsequent anti-lymphoma treatment.","reportingStatus":"POSTED","timeFrame":"Median duration of follow-up of 40 months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Days"}